Hybrid immunity elicits potent cross-variant ADCC against SARS-CoV-2 through a combination of anti-S1 and S2 antibodies
M. D. Grant, K. Bentley, C. A. Fielding, K. M. Hatfield, D. P. Ings, D. Harnum, E. Wang, R. Stanton, K. A. Holder
This study shows that hybrid immunity, from prior infection followed by vaccination, generates stronger and broader antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 variants than vaccination alone.
bioRxiv · Mar 9, 2023 · PreprintImmunology